Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The First Shall Be Fifth: Salix’s Recombinant C1 Esterase Inhibitor Enters Crowded HAE Market

Jul 18 2014

Related Content

Pharming/Santarus’ Recombinant HAE Drug <em>Ruconest </em>Goes Back To FDA

Apr 18 2013

Is Europe's HAE Market Big Enough To Sustain All The Competitors?

Mar 21 2011

Shire To Test Convenience Versus Familiarity In HAE With Approval Of <i>Firazyr</i>

Aug 29 2011

Related Companies

Salix Pharmaceuticals Ltd.

Takeda Pharmaceutical Co. Ltd.

CSL Limited

Dyax Corp

Santarus, Inc.

Pharming Group N.V.

Cosmo Pharmaceuticals N.V.

Additional Topics

United States BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window